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ABSTRACT 
 
Objective: To assess the cost-effectiveness of bivalirudin versus heparin and glycoprotein 
IIb/IIIa inhibitor (H-GPI) in patients undergoing primary percutaneous coronary intervention 
(PPCI) for acute ST-segment elevation myocardial infarction (STEMI), from a UK health 
service perspective. 
Design: Cost-utility analysis with life-long time horizon. 
Main outcome measures: Costs, quality-adjusted life-years (QALYs) and incremental cost-
effectiveness. 
Methods: Event risks and medical resource use data derived from the HORIZONS-AMI trial 
were entered into a decision analytic model. Clinical events until the end of year 1 (main 
model) or year 3 (alternative model) were modelled in detail. Adjustments were applied to 
approximate UK routine practice characteristics. Life expectancy of 1-year or 3-year 
survivors, health-state utilities, initial hospitalisation length of stay in the comparator strategy 
and unit costs were based on UK sources. Costs and effects were discounted at 3.5%. 
Results: The main model predicted bivalirudin and H-GPI patients to survive 11.52 and 11.35 
(undiscounted) years on average, respectively, and to accrue 6.26 and 6.17 QALYs. Patient 
lifetime costs were £267 lower in the bivalirudin strategy (£12,843 versus £13,110). Extensive 
sensitivity and scenario analyses confirmed these results to be robust. In probabilistic 
analysis, quality-adjusted survival was higher and costs were lower with bivalirudin, in 95.0% 
of simulation runs. In 99.2%, cost-effectiveness was better than £20,000 per QALY gained. 
Results from the alternative model were fully consistent. 
Conclusion: The use of bivalirudin instead of H-GPI in STEMI patients undergoing PPCI is 
cost-effective, and offers a high probability of dominance. Background treatment with aspirin 
and clopidogrel is assumed.
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INTRODUCTION 
 
Primary percutaneous coronary intervention (PPCI) has emerged as the preferred treatment 
option for acute ST-segment elevation myocardial infarction (STEMI) internationally and in 
the United Kingdom (UK).[1, 2] It has substantially reduced condition-related morbidity and 
mortality.[3] The addition of glycoprotein IIb/IIIa inhibitors (GPIs) to heparin-based 
anticoagulation has contributed to the decrease in ischaemic event rates but has increased the 
risk of bleeding complications.[4] 
Bivalirudin, a direct and specific thrombin inhibitor, represents an alternative to the use of 
heparin and a GPI (H-GPI), against a common background of standard treatment with aspirin 
and clopidogrel. The Harmonizing Outcomes with Revascularization and Stents in Acute 
Myocardial Infarction (HORIZONS-AMI) trial (ClinicalTrials.gov number, NCT00433966), 
an international, prospective, randomised, open-label, parallel-group, Phase III clinical trial, 
established the comparative clinical efficacy and safety of this alternative in acute STEMI 
patients undergoing PPCI.[5] In this study, 57.2% of 3,602 patients were enrolled in Europe 
and 2.8% in the UK. Bivalirudin showed a significant reduction in mortality and post-
procedural bleeding events, with similar ischaemic event rates, at 30 days.[5] These effects 
were sustained at one year and three years.[6, 7] Furthermore, at three years, a significant 
reduction in repeat myocardial infarctions (MIs) was observed, mainly driven by non-Q-wave 
events. These results are consistent with findings from earlier randomised trials in related 
indications [8, 9] and retrospective analyses of large patient databases in the USA.[10, 11] 
There are no other randomised comparisons addressing the same clinical question. 
HORIZONS-AMI therefore formed the basis of European Medicines Agency approval of 
bivalirudin use for PPCI. 
The health economic implications of bivalirudin use in STEMI patients undergoing PPCI 
in the UK have recently been assessed as part of a National Institute for Health and Clinical 
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Excellence Single Technology Appraisal.[12] The present analysis of the incremental costs 
and cost-effectiveness of bivalirudin, conducted from a UK National Health Service 
perspective, was provided for the NICE appraisal. 
 
 
METHODS 
 
Overview 
We performed a model-based cost-utility analysis with a life-long time horizon. The model 
evaluated incremental costs, and incremental clinical effectiveness expressed as quality-
adjusted life-years (QALYs) gained. The bivalirudin-based and H-GPI-based treatment 
strategies were equivalent to those in the HORIZONS-AMI trial. Details and dosing rules 
have been reported elsewhere.[5] As defined in the trial protocol, provisional use of GPI was 
allowed in bivalirudin-treated patients that experienced no reflow or giant thrombus after PCI. 
All patients received aspirin and a thienopyridine prior to angiography. 
The full HORIZONS-AMI dataset served as the main data source for this analysis. 
Absolute and relative clinical event risks and resource use parameters were derived from the 
HORIZONS-AMI intention-to-treat population. However, in order to adapt the data to the UK 
environment, assumptions on the use of radial arterial access; the proportional use of 
alternative GPIs, and initial length of stay in the H-GPI strategy were made. The long-term 
life expectancy of STEMI patients, utility values (i.e. quality of life weights) and unit costs 
were drawn from UK sources. A similar approach was previously used in a cost-effectiveness 
analysis of bivalirudin in the treatment of non-ST-segment elevation acute coronary syndrome 
(NSTE-ACS).[13] Details on model assumptions and input parameters are provided below 
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and in an online supplement. Tables 1-3 list the parameters used in the main analysis as well 
as related ranges of variation and distributional assumptions required for sensitivity analysis. 
 
Model structure 
The health economic model was implemented using a published structure that combines a 
decision tree model with a Markov model to cover long-term survival.[13] Simulated patient 
cohorts entered the model at age 60.9 years, the mean age of the HORIZONS-AMI 
population, and were followed from primary hospitalisation to death. It was assumed that 
patients would not survive beyond age 100. The assumption was made that initial 
angiography was performed on all patients. The majority then received PPCI. Coronary artery 
bypass graft (CABG) surgery or medical management were used in a small fraction. Between 
this initial treatment and the end of year 1, possible events included major and minor 
bleeding, ischaemic stroke, repeat MI, repeat revascularisation, or death (main model; fig. 1). 
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Table 1. Absolute and relative clinical event risks 
 Patients (%; 95% CI)a Patients (%; 95% CI)a  
Relative event risk; 95% CIa 
Type of clinical 
event 
H-GPI arm, 1 year H-GPI arm, 3 years Bivalirudin arm, 1 
year 
Bivalirudin versus 
H-GPI 
Bivalirudin arm, 3 
years  
Bivalirudin versus 
H-GPI 
HORIZONS-AMI trial 
Non-CABG-related 
major bleedingb 
165 (9.2; 7.9-10.6) 185 (10.3; 8.9-11.8) 103 (5.7; 4.7-6.9)  
0.63; 0.49-0.79 
121 (6.7; 5.6-8.0)  
0.66; 0.53-0.82 
Non-CABG-related 
major access site 
bleedingc 
64 (3.6; 2.7-4.5) 67 (3.7; 2.9-4.7) 34 (1.9; 1.3-2.6)  
0.53; 0.35-0.80 
39 (2.2; 1.5-3.0)  
0.58; 0.39-0.86 
Non-CABG-related 
major non-access 
site bleedingc 
101 (5.6; 4.6-6.8) 118 (6.5; 5.4-7.8) 69 (3.8; 3.0-4.8) 
0.68; 0.51-0.92 
82 (4.6; 3.6-5.6)  
0.70; 0.53-0.92 
Non-CABG-related 
minor bleeding 
256 (14.2; 12.6-
15.9) 
262 (14.5; 12.9-
16.3) 
137 (7.6; 6.4-8.9)  
0.54; 0.44-0.65 
146 (8.1; 6.9-9.5) 
0.56; 0.46-0.68 
Ischaemic stroke 18 (1.0; 0.6-1.6) 31 (1.7; 1.2-2.4) 19 (1.1; 0.6-1.6)  
1.06; 0.56-2.01 
27 (1.5; 1.0-2.2)  
0.87; 0.52-1.46 
Repeat myocardial 
infarction 
76 (4.2; 3.3-5.3) 135 (7.5; 6.3-8.8) 62 (3.4; 2.7-4.4)  
0.82; 0.59-1.14 
105 (5.8; 4.8-7.0)  
0.78; 0.61-0.97 
Repeat 
revascularisation 
155 (8.6; 7.3-10.0) 302 (16.8; 15.1-
18.6) 
174 (9.7; 8.3-11.1)  
1.12; 0.91-1.38 
337 (18.7; 16.9-
20.6)  
1.12; 0.97-1.29 
Death 86 (4.8; 3.8-5.9) 134 (7.4; 6.3-8.7) 61 (3.4; 2.6-4.3)  
0.71; 0.52-0.98 
102 (5.7; 4.6-6.8)  
0.76; 0.59-0.98 
Estimates for 42.5% radial arterial access use as assumed in the base case analysisd 
Non-CABG-related 
major bleedingb 
138 (7.7; 6.5-9.0) 157 (8.7; 7.5-10.1) 89 (4.9; 4.0-6.0)  
0.64; 0.50-0.82 
104 (5.8; 4.7-7.0)  
0.67; 0.53-0.83 
Non-CABG-related 
major access site 
bleedingc 
37 (2.1; 1.4-2.8) 39 (2.2; 1.5-2.9) 20 (1.1; 0.7-1.7)  
0.53 (0.32-0.93) 
22 (1.2; 0.8-1.8)  
0.58 (0.34-0.95) 
Non-CABG-related 
minor bleeding 
147 (8.2; 6.9-9.5) 151 (8.4; 7.1-9.8) 79 (4.4; 3.5-5.4)  
0.54; 0.44-0.66 
84 (4.7; 3.7-5.7)  
0.56; 0.45-0.69 
a Based on Kaplan-Meier estimates of event numbers for the HORIZONS-AMI intention-to-treat population. 
H-GPI arm, N = 1,802; bivalirudin arm, N = 1,800. Limits of 95% CIs were used as ranges of variation in 
sensitivity analysis. In probabilistic sensitivity analysis, absolute (comparator strategy) event risks were 
represented by beta distributions and relative event risks by lognormal distributions. 
b The HORIZONS-AMI definition of major bleeding included any of intracranial bleeding; intraocular 
bleeding; retroperitoneal bleeding; access site haemorrhage requiring surgery; haematoma ≥5 cm; reduction 
in haemoglobin of ≥4 g/dL without overt source; reduction in haemoglobin of ≥3 g/dL with overt source; re-
operation for bleeding; use of any blood transfusion.[5] 
c Patients with a non-CABG major bleeding were classified as “access site” if they had a reported arterial 
access site or retroperitoneal bleeding, but no other major bleeding. The remainder of patients with a major 
bleeding were classified as “non-access site”. An equivalent definition was recently used by Verheugt et 
al.[14] 
d Estimates based on assumption of no access site bleedings in patients with radial arterial access (see 
Methods, section on Clinical event risks). 
CABG, coronary artery bypass graft; H-GPI, heparin and glycoprotein IIb/IIIa inhibitor; HORIZONS-AMI, 
Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction; n/e, not estimated. 
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In order to avoid double counting, stent thrombosis was not modelled separately but its health 
impact and economic consequences are implicit by the modelling of the aforementioned 
events. In an alternative model, detailed modelling of clinical events was extended until the 
end of year 3 and the model structure was amended to maintain correct discounting despite 
this change. Average strategy-specific survival times of patients who died during year 1 or 
years 1-3 were taken into account. After the first or third year, survival was modelled based 
on published life expectancies. No further clinical events were modelled in detail. The 
Markov module used two disease stages (alive/dead). Cycle length was one year and a half-
cycle correction was applied. Over the lifetime of the simulated cohorts, medical resource use, 
costs and QALYs accumulated. Costs and effects were discounted at 3.5% per year.[15] 
 
Model inputs 
Clinical event risks 
A full set of HORIZONS-AMI-based 1-year and 3-year comparator strategy event risks and 
of corresponding relative risks in the bivalirudin strategy (Table 1) was derived for the 
purpose of this analysis, and was found to be consistent with published results.[5-7] 
Radial arterial access is more frequently used in the UK than in the HORIZONS-AMI 
patients (214, 5.9%). In order to account for this difference, the base case analysis assumed 
use of the radial route in 42.5% of patients, as per BCIS audit data.[16] The assumption was 
made that there would be no access site bleedings in these patients. The risk of non-access site 
bleeding was left unchanged.[17] The absolute bleeding risk in the comparator strategy and 
the resulting absolute effect of bivalirudin use on bleeding were hence reduced. The reduced 
risk difference for non-CABG major bleeding was assumed to lead to a proportional reduction 
in the length of stay difference between treatment strategies. 
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Table 2. Utilities, medical resource use and long-term life expectancy 
Parameter Base case 
value 
Range of variation in 
sensitivity analysisa 
Basis of 
variation; 
distribution in 
PSA 
Life expectancy (years)[18-20] 
 1-year survivors, at end of year 1 
 3-year survivors, at end of year 3 
 
11.26 
9.37b 
 
8.45-14.08 
7.03-11.71 
 
±25%; triangular 
Utility scores[21] 
 First year after STEMI event 
 Subsequent years 
 
0.68 
0.72 
 
0.60-0.76 
0.65-0.79 
 
Utility 
decrement 
±25%; triangular 
Anticoagulant use, % of patients 
 GPI (H-GPI; bivalirudin) 
 Bivalirudin (bivalirudin) 
 
95.3%; 7.6% 
96.9% 
 
--
c
 
-- 
 
n/a 
 
Anticoagulant vial numbers, meand 
 Abciximab 10 mg (H-GPI; bivalirudin) 
 Eptifibatide 20 mg (H-GPI; bivalirudin) 
 Tirofiban 12.5 mg (H-GPI; bivalirudin) 
 Bivalirudin 250 mg (bivalirudin) 
 
3.07; 2.80 
1.88; 1.64 
1; 1 
1.23 
 
3.03-3.11; 2.63-2.96 
1.84-1.92; 1.50-1.78 
--
c
 
1.21-1.26 
 
95% CI; gamma 
Initial hospitalisation days, mean 
 Normal ward (H-GPI) 
 ICU/CCU (H-GPI) 
 Normal ward (∆ bivalirudin – H-GPI) 
 ICU/CCU  (∆ bivalirudin – H-GPI) 
 
2.45 
1.95 
0.06 
-0.32 
 
2.28-2.65e,f 
1.76-2.16e,f 
(-0.11)-0.32e 
(-0.48)-(-0.17)e 
 
95% CI; gamma 
 
95% CI; 
lognormalg 
Estimates for 42.5% radial arterial access use as assumed in the base case analysisd 
Initial hospitalisation days, mean 
 Normal ward (∆ bivalirudin – H-GPI) 
 ICU/CCU  (∆ bivalirudin – H-GPI) 
 
0.05 
-0.25 
 
(-0.21)-0.33e 
 (-0.49)-0.01e 
 
95% CI; 
lognormalg 
a Only covering sensitivity analyses addressing the impact of parameter uncertainty. Additional scenario 
analyses are described in the text and in the online supplement.  
b In the alternative model (with detailed modelling of adverse events until the end of year 3), overall survival 
in the comparator strategy was made identical to that seen in the main model. 
c Varied in scenario analysis. 
d Mean per patient in whom substance was used. The means shown originate from integer vials numbers at 
the patient level; non-integer values were increased to the next integer. For example, in the case of 
bivalirudin, this resulted in 1-3 vials per patient; in the vast majority of patients one vial was used. 
e Based on bias-corrected bootstrap results using 1,000 replications. 
f CIs do not take into account uncertainty in the H-GPI strategy overall length of stay assumption of 4.4 
days.[22] 
g In the model, these length of stay differences between strategies were implemented using multiplication 
factors that were assigned lognormal distributions. 
CI, confidence interval; ∆, difference; H-GPI, heparin and glycoprotein IIb/IIIa inhibitor; ICU/CCU, intensive 
care unit/coronary care unit; n/a, not applicable; PSA, probabilistic sensitivity analysis; STEMI, ST-segment 
elevation myocardial infarction. 
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Long-term survival 
Long-term survival (beyond 1 year of follow-up in the main model and beyond 3 years in the 
alternative model) was based on an estimate using Nottingham Heart Attack Register 
(NHAR) data (Table 2).[20] Life-tables for England and Wales and the DEALE method were 
used to adjust this estimate to the increase in overall life expectancy since the NHAR data 
were collected, and to the mean age of the HORIZONS-AMI patients (S1.1, online).[18, 19] 
For those who survived the initial one-year or three-year period, long-term survival was 
assumed to be independent of the initial anticoagulation strategy. 
 
Utilities 
European Quality of Life-5 Dimensions-based health-state utilities from a single-centre UK 
study of 229 consecutive MI survivors (Table 2) were applied.[21] Valuation used standard 
UK time trade-off values and results were comparable to an independent set of UK estimates 
for PCI patients.[23] 
 
Medical resource use 
Anticoagulant vial use during the initial hospitalisation was derived from the HORIZONS-
AMI data (Table 2). Non-integer vial numbers at patient-level were increased to the next 
integer in order to cover waste of leftovers. Per-protocol GPI use was restricted to abciximab 
and eptifibatide. In order to reflect UK practice, the proportional use of alternative GPIs in 
UK PCI patients in 2009, i.e. abciximab, 73.0%; eptifibatide, 8.1%; tirofiban 18.9%, was 
applied under the assumption of a GPI class effect and, hence, no changes in clinical 
effectiveness (S1.2, online).[16] Unfractionated heparin was disregarded due to its low cost. 
Initial hospitalisation length of stay in the H-GPI strategy was assumed to be 4.4 days 
(compared to 7.2 days in HORIZONS-AMI).[22] The relative length of stay reduction 
observed in HORIZONS-AMI was applied to estimate length of stay in the bivalirudin 
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strategy (Table 2; S1.3, online). In the base case analysis and applicable sensitivity analyses, 
the resulting difference was reduced in order to reflect the potential impact of a lower 
incidence of access site bleeding in conjunction with substantial radial arterial access use in 
the UK (see Clinical event risks). 
Other resource items or drivers of resource use taken into account during the initial 
hospitalisation period and until the end of the first year (or third year, in the alternative 
analysis) included diagnostic angiograms, PCI and CABG procedures as well as clinical 
events (i.e. bleeding, ischaemic stroke, repeat MI and death; S1.4, online). After the first or 
third year, long-term cardiovascular-related medical resource use was represented by a 
literature-derived annual amount for a surviving patient. This amount was estimated from a 
published model of thrombolysis versus primary PCI in MI patients and designed to also 
incorporate the impact of repeat MIs and strokes on a summary basis (Table 3; S1.5, 
online).[24] The same amount was used to represent annual cardiovascular outpatient 
treatment and drug use during the first year or the first three years. 
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Table 3. Unit costs 
Parameter Base case 
value (£)a 
Range of 
variation in 
sensitivity 
analysis 
Basis of 
variation; 
distribution type 
in PSA 
Drug costs[25] 
 Abciximab (ReoPro®) 10 mg vial 
 Eptifibatide (Integrilin®) 20 mg; 75 mg vial 
 Tirofiban (Aggrastat®) 12.5 mg vial 
 Bivalirudin (Angiomax®) 250 mg vial 
 
250 
14; 43 
161 
310 
 
--
b
 
--
b
 
--
b
 
--
b
 
 
n/a 
Event and procedure costs 
 Angiography procedure costc [26] 
 PCI cost [27] 
 PCI procedure costc [27, 28] 
 CABG cost [27] 
 CABG procedure costc [27, 29] 
 Q-wave MI [27] 
 Non-Q-wave MI  [27, 30] 
 Ischaemic stroke cost [31] 
 Ischaemic stroke non-ward costc [27, 31] 
 Major bleed cost [27, 32] 
 Major bleed non-ward costc [27, 32] 
 Minor bleed cost [27, 32] 
 Minor bleed non-ward costc [27, 32] 
 
283 
3,152 
1,733 
8,372 
3,115 
1,746 
541 
10,611 
8,873 
2,364 
1,300 
144 
79 
 
269-501 
2,278-3,865 
1,253-2,126 
6,690-9,707 
2,489-3,611 
1,291-2,011 
400-623 
5,306-15,917 
4,436-13,309 
1,182-3,545 
650-1,950 
72-216 
40-119 
 
IQR; triangular 
 
 
 
 
 
 
±50%; uniform 
Ward costs  
 Normal ward day [33] 
 CCU/ICU day [27] 
 
274 
814e 
 
--
d
 
--
d
 
 
n/a 
Long-term annual cardiovascular treatment cost of 
1-year or 3-year survivorsf [24] 
900 450-1,350 ±50%; uniform 
a Unit costs at 2009-10 prices. Inflated from older values where required.[34] 
b Unit costs of anticoagulant vials were not varied as they were not subject to parameter uncertainty. 
c Excluding ward costs. 
d Not varied in sensitivity analysis as variation of length of stay in the comparator strategy was assumed to 
also cover uncertainty in these unit cost estimates. 
e Simple average of NHS reference costs for intensive care unit and coronary care unit. See online 
supplement. 
f Also used to represent annual cardiovascular outpatient treatment and drug costs in year 1 (years 1-3, in the 
alternative model). 
IQR, inter-quartile range; HRG, Healthcare Resource Group; ICU/CCU, intensive care unit/coronary care unit; 
n/a, not applicable; NHS, National Health Service; PSA, probabilistic sensitivity analysis. 
 
Unit costs 
Unit costs were at 2009-10 prices; where necessary, older unit costs were inflation-corrected 
accordingly (Table 3; S1.5, online).[34] Public drug prices were taken from the MIMS 
website.[25] Ward costs and unit costs of angiography, PCI, CABG and repeat MI were based 
on NHS reference costs. The impact of PCI-related bleeding was partially covered by 
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modelling initial hospitalisation ward costs. Additional examination and procedure costs of a 
HORIZONS-AMI major bleeding[5] were estimated to be 75% of the procedure cost of a 
repeat PCI. This estimate relied on a comparison of the impact of bleedings and repeat PCI 
procedures on hospitalisation costs, as assessed by multivariate regression methods (S1.5, 
online).[32, 35] HORIZONS-AMI minor bleedings were assumed to cost 6% of a major 
bleeding.[32] 
 
Sensitivity analysis 
Due to imperfect information on the costs and clinical effectiveness of the treatments studied, 
cost-effectiveness results are necessarily subject to uncertainty. This implies a potential to 
misinform decision makers. In order to assess this potential in the present case, major inputs 
into the main model were subjected to deterministic and probabilistic sensitivity testing. We 
included comparator strategy event risks, relative risks in the bivalirudin strategy, utilities, 
length of stay parameters, anticoagulant vial numbers, procedure costs and clinical event 
costs. Estimates of bleeding costs, of cardiovascular outpatient treatment and drug costs in the 
first year, and of long-term annual cardiovascular treatment costs were varied by ±50% and 
with uniform distributions, to reflect increased parameter uncertainty. Ranges of variation and 
distribution types are available from Tables 1-3. A probabilistic analysis of the alternative 
model was additionally run and followed an equivalent approach. 
Scenario analyses were performed in order to gain a better understanding of the 
applicability of main results to variations in UK practice. HORIZONS-AMI-based comparator 
strategy event risks were replaced with a tentative set of UK-based event risks compiled from 
different sources (S2.1, online). In order to assess the impact of varying use of radial arterial 
access, we replaced the value reported by BCIS, of 42.5%, with 5.9% as seen in HORIZONS-
AMI and with an extreme assumption of 100%. The effects of bivalirudin on bleeding 
occurrence and length of stay were adjusted accordingly. In an additional step, we also 
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reduced the survival advantage for bivalirudin in patients with radial arterial access. For this 
purpose, the entire survival difference between strategies was conservatively assumed to be 
due to major bleeding avoidance. The mortality increase associated with major access-site 
bleeding was further assumed to be half of the increase associated with major non-access-site 
bleeding.[14, 36] 
 
The proportional use of alternative GPI substances reported by BCIS[16] was replaced with 
abciximab 100% as assumed in the National Infarct Angioplasty Project (NIAP) 
modelling;[22] with abciximab 52.9% and eptifibatide 47.1% as observed in HORIZONS-
AMI; and with eptifibatide 100%, reflecting the lowest possible GPI cost. The initial 
hospitalisation was assumed to be of equal duration in both strategies. An extreme case 
scenario combined assumptions of 100% radial arterial access use, of a correspondingly 
reduced survival advantage for bivalirudin, of 100% eptifibatide use (in patients receiving a 
GPI) and of no difference in initial hospitalisation length of stay between strategies. The 
discount rate was varied from 0-6%. (Additional analyses are described in S2.2, online.) 
 
Technical implementation 
Derivations of model inputs and related statistical analyses were performed in Stata/MP®, 
Release 11 (Stata Corporation, College Station, TX, USA). The health economic model was 
implemented in TreeAge Pro 2009 Suite® (TreeAge, Inc., Williamstown, MA, USA). 
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RESULTS 
 
Survival 
In the main and alternative models (with detailed modelling of clinical events until the end of 
year 1 and year 3), undiscounted survival after the index event in the bivalirudin strategy was 
predicted to be 11.52 and 11.56 years, respectively. Undiscounted survival in the H-GPI 
strategy was predicted to be 11.35 years in both cases. The implied small differences of 0.17 
and 0.21 years arose from an absolute reduction of risk of death of 1.4% after year 1 
(bivalirudin strategy, 3.4%; H-GPI strategy, 4.8%) and of 1.7% after year 3 (bivalirudin 
strategy, 5.7%; H-GPI strategy, 7.4%). 
 
Cost and cost effectiveness 
Cost differences between strategies and incremental cost-effectiveness results for the main 
and alternative models are shown in Table 4. In both models, the bivalirudin strategy was less 
costly than the H-GPI strategy. This was mainly driven by lower anticoagulant and initial 
hospitalisation ward costs. Procedure and clinical event costs were also lower. In contrast, 
cardiovascular outpatient treatment and drug costs during the initial one-year or three-year 
period, and long-term cardiovascular treatment costs, were higher in the bivalirudin strategy, 
as a reflection of improved survival. The life-long cost advantage for bivalirudin amounted to 
£267 and £250 in the main and alternative models, respectively, and went along with 
incremental gains of 0.09 and 0.11 QALYs. In combination, these results indicate a situation 
of dominance of bivalirudin over H-GPI, i.e. the bivalirudin strategy was more clinically 
effective and cost saving. 
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Table 4. Cost (£ per patient) and cost-effectiveness results 
Parameter Main modela Alternative modela 
 Bivalirudin H-GPI ∆ Bivalirudin H-GPI ∆ 
Cost of bivalirudin 370 0 370 370 0 370 
Cost of GPI 42 573 -531 42 573 -531 
Ward cost (initial hospitalisation) 2,064 2,259 -195 2,064 2,259 -195 
Procedure and clinical event cost 
during year 1 / years 1-3b,c 
2,484 2,509 -25 2,903 2,939 -36 
Cardiovascular outpatient 
treatment and drug cost in year 1 / 
years 1-3c 
876 864 12 2,508 2,470 38 
Total cost in year 1 / years 1-3c 5,837 6,204 -367 7,886 8,241 -355 
Long-term cardiovascular 
treatment cost after year 1 or year 
3c 
7,006 6,906 100 5,593 5,489 104 
Total costc 12,843 13,110 -267 13,480 13,730 -250 
QALYs per patientc 6.26 6.17 0.09 6.43 6.32 0.11 
ICER (£ per QALY gained)c Bivalirudin strategy dominantd Bivalirudin strategy dominantd 
a In the main model, detailed modelling of clinical events covered the first year after the initial STEMI event. 
In the alternative model, this time period was extended to three years. 
b Excluding initial hospitalisation ward costs. 
c Discounted at 3.5% per year, starting in year 2. 
d If one strategy dominates the alternative, i.e. if it is more clinically effective and less costly, calculating an 
ICER is numerically possible but the result has no meaningful interpretation. Differences in effectiveness 
and cosr are therefore shown side-by-side. 
∆, difference; GPI, glycoprotein IIb/IIIa inhibitor; H-GPI, heparin and glycoprotein IIb/IIIa inhibitor; ICER, 
incremental cost-effectiveness ratio; QALY, quality-adjusted life year. 
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Sensitivity and scenario analyses 
The dominance of bivalirudin was maintained in all deterministic sensitivity analyses 
exploring the impact of parameter uncertainty, except if the length of stay differences between 
strategies in normal ward and in intensive or coronary care were varied jointly on the basis of 
their 95% confidence intervals (CIs). This led to a net cost of the bivalirudin strategy of £37, 
resulting in an incremental cost-effectiveness ratio (ICER) of £415 per QALY gained. 
Detailed sensitivity and scenario analysis results are available online (S3). 
In the probabilistic sensitivity analysis (fig. 2), the bivalirudin strategy was dominant 
(i.e. was cost-saving and showed a QALY gain) in 9,501 (95.0%) of 10,000 simulation runs. 
The cost-effectiveness threshold of £20,000 per QALY gained was met in 9,924 (99.2%) of 
10,000 runs. Probabilistic analysis of the alternative model yielded similar results. 
The dominance of bivalirudin was also maintained in most of the scenario analyses. It 
was lost but a favourable ICER of £1,764 per QALY gained was still seen when eptifibatide 
was assumed to be the only GPI used. In the extreme case scenario combining several 
unfavourable assumptions (100% eptifibatide use; 100% radial arterial access use with a 
correspondingly reduced survival advantage for bivalirudin; no difference in initial 
hospitalisation length of stay), the ICER was £5,428 per QALY gained. 
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DISCUSSION 
 
Our incremental cost-effectiveness analysis indicates that, in STEMI patients undergoing 
PPCI, the use of bivalirudin yields a QALY gain and is cost-saving compared to H-GPI-based 
anticoagulation. It is hence dominant from the perspective of the UK health system. Results 
from two model versions, with detailed modelling of clinical events until the end of year 1 or 
year 3, are highly consistent. Dominance is maintained over a wide range of sensitivity and 
scenario results. Even under very unfavourable assumptions, the incremental cost-
effectiveness remains better than £6,000 per QALY gained. 
 
Comparison with published studies 
To our knowledge this is the first incremental cost-effectiveness analysis of bivalirudin use in 
PPCI. Guidance documents issued by NICE and by the Scottish Medicines Consortium were 
informed by the analysis presented here and by an earlier version reflecting the Scottish 
setting.[12, 37] A previous cost-effectiveness analysis for UK patients with NSTE-ACS used 
the same analytical framework but favoured bivalirudin less strongly than the present 
analysis.[13] This result is consistent given smaller clinical effect sizes and longer 
anticoagulant and GPI administration times. Other economic studies of bivalirudin were 
mostly cost studies with limited time horizons. They reported bivalirudin use to be cost saving 
in different indications.[38] A large administrative database study of PPCI patients in the 
USA found that from a hospital perspective, 30-day costs were 9% lower if bivalirudin was 
used instead of H-GPI.[39] This result matches the 9% cost difference we found in our 
analysis at the end of year 1. 
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Strengths and weaknesses 
International randomised clinical trial results representing a high level of clinical evidence 
formed the basis of this analysis. It should be noted that the HORIZONS-AMI trial used an 
open-label design to cope with technical complexities.[5] Predominant use of the 
HORIZONS-AMI intention-to-treat data allowed for a high level of internal consistency of 
model input parameters. The use of local data on long-term survival, utilities, length of stay 
and unit costs allowed for an adjustment to the UK health service environment. However, 
issues of transferability of clinical trial results remain and some related adjustments are 
subject to limitations. For example, results for the 214 HORIZONS-AMI patients with radial 
arterial access were affected by unacceptable statistical uncertainty. Approximation of the 
impact of radial access use was therefore based on assumptions of no access site bleedings in 
the affected patients and of a reduced length of stay advantage for bivalirudin. Initial 
hospitalisation length of stay in the H-GPI strategy was taken from a UK source[22] and the 
reduction seen in the HORIZONS-AMI bivalirudin arm was applied proportionally. It is 
unproven whether such a proportional reduction can actually be achieved in UK routine 
practice, although two US database analyses have observed such an effect.[10, 39] The use of 
alternative GPI substances in HORIZONS-AMI was influenced by the protocol. For an 
adjustment to UK practice, data on all PCI patients in the UK were available but no data on 
STEMI PPCI patients.[16] Thus, the use of abciximab, the most expensive GPI, was probably 
underestimated. In fact, a modelling study by Goodacre et al. that formed part of the English 
NIAP project assumed 100% abciximab use in STEMI PPCI patients treated with H-GPI.[22] 
Estimating long-term survival required adjustment of data collected 10-15 years ago.[20] 
The approach to sensitivity analysis took into account increased parameter uncertainty 
in some model inputs such as long-term annual cardiovascular treatment costs and bleeding 
costs, which arose from lack of data. A possible reduction of the survival advantage for 
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bivalirudin in situations of increased use of radial arterial access was approximated in 
scenario analysis. The impact on cost-effectiveness was rather limited. 
Structurally, the model did not link long-term survival and costs to the occurrence of 
clinical events during the initial one-year or three-year period. Given a lack of suitable input 
data, identical mortality risks were assumed for survivors of this period. However, the 
alternative model (with detailed modelling of clinical events until the end of year 3) 
demonstrated differential survival rates and a sustained survival advantage in years 2 and 3 
for bivalirudin-treated patients, which resulted in an increased QALY gain. Hence, the above 
assumption may have biased results towards the conservative. While the model correctly 
covered the occurrence of multiple events of different type in one patient, a simplifying 
assumption of a maximum of one clinical event per event type and patient was made. The 
impact of this choice was assessed to be marginal. The utility impact of clinical events after 
the initial STEMI event was covered on a summary basis but could not be based on the actual 
pattern of event occurrence in the HORIZONS-AMI trial, where more events occurred in the 
H-GPI strategy. 
Some practical advantages of bivalirudin such as simpler administration and reduced 
monitoring requirements were not taken into account. 
 
Further research 
We focused on comparing bivalirudin against H-GPI which is considered the current standard 
of care.[1, 2] A common background treatment of aspirin and a thienopyridine was assumed; 
in the HORIZONS-AMI trial, clopidogrel was overwhelmingly used. Our results are therefore 
only formally valid for this approach. Combination with newer thienopyridines such as 
prasugrel requires further study but there are no obvious reasons to expect fundamentally 
different health economic characteristics.[40] Alternative comparator strategies such as 
heparin and provisional GPI or heparin alone would require evaluation in large randomised 
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trials of STEMI patients; for heparin alone indirect treatment comparisons using older trials of 
heparin alone versus H-GPI might be used for an approximate assessment. Based on subgroup 
analyses of the HORIZONS-AMI data and observational studies, it is currently being 
discussed whether bivalirudin should be administered in conjunction with heparin.[41-43] 
Given the minimal cost of heparin, a negative impact on the cost-effectiveness of bivalirudin 
would be unlikely. 
In order to gain additional insights into the implications of bivalirudin use in the UK, 
clinical registries of STEMI PPCI patients could be used. Studies of mixed PCI populations 
conducted in the USA indicate the feasibility of observational approaches.[10, 39] In order to 
provide meaningful data, registries should record details of anticoagulation strategies and 
related drug use and bleeding events, in addition to standard parameters. Mechanisms should 
be implemented to avoid underreporting of bleeding events. The duration of clinical follow-up 
should be at least one year. 
 
Conclusion 
In STEMI patients undergoing PPCI, the use of bivalirudin instead of H-GPI is cost-effective, 
and offers a high probability of dominance, from the perspective of the UK health system. 
Background treatment with aspirin and clopidogrel is assumed. Extensive sensitivity and 
scenario analyses confirmed this result to be robust. 
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FIGURE LEGENDS 
 
Figure 1. Structure of decision analytic model 
 
Figure 2. Main model - probabilistic sensitivity analysis results 
 


